Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
8.23 K
Value Traded
90.51
Short % Float
-
Days to Cover
193.4
0%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NKGN Catalyst Timeline
Dated clinical, regulatory and corporate events for NKGen Biotech, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NKGen Biotech, Inc.
5Total events
2Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
Event history 2
◆Oral PresentationtroculeucelPresentation
NKGen CEO to present troculeucel data in neurodegenerative diseases at 4th Great Bay Cell and Gene Therapy Forum
neurodegenerative diseasessource ↗
◆Oral PresentationtroculeucelPresentation
NKGen CEO to present on troculeucel in neurodegenerative diseases at Biologics Manufacturing Korea 2026
neurodegenerative diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How NKGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every NKGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CFIC-2015 NV Family Investments, LLC10% Owner | Buy | 19,669,552 21,752,885 held | $0.13 | 05/27/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in NKGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NKGN for Q2 2026. | ||||
Ownership Trends
NKGN Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
660.5K
Shares Sold Short
0.0% vs prior count
193.4 Very high
Days to Cover
trading days of normal volume to buy every short share back
3.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NKGN ranks across every disease it competes in
Competitive Position is a premium feature
See how NKGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNKGN News
-NKGN
Nov 9, 2026NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026
NKGen Biotech will present findings on troculeucel at the CTAD 2026 Conference. The poster will detail cognitive outcomes from a patient with moderate Alzheimer's disease who received extended treatment. This follows a Phase 1 study and highlights the therapy's potential benefits over an additional 12 months.
Read more →-NKGN
Sep 15, 2026NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
NKGen Biotech will present its investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum in Guangzhou, China, on September 23, 2026. The presentation will focus on troculeucel's application in neurodegenerative diseases, including Alzheimer’s and Parkinson’s. The company aims to discuss its mechanism of action and clinical experiences with the therapy.
Read more →-NKGN
Sep 10, 2026NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
NKGen Biotech will present on troculeucel's potential for treating neurodegenerative diseases at Biologics Manufacturing Korea 2026. The presentation will cover its mechanism of action and clinical experiences in conditions like Alzheimer's and Parkinson's disease. The event is scheduled for September 18, 2026, in Incheon, South Korea.
Read more →-NKGN
Oct 9, 2025▲ +66.7%on this news· ran to +3233% by day 3
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics
Read more →-NKGN
Jul 16, 2025NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards
NKGen Biotech has raised $2 million from a Japanese investor to regain compliance with SEC reporting obligations. The funding will support their Phase 2 clinical trial for troculeucel, a novel NK cell therapy. The company plans to move from the OTC Pink to the Expert Market temporarily and aims to uplist to OTCQB and eventually to Nasdaq. This strategic investment follows challenges from the bankruptcy of their former parent company.
Read more →-NKGN
May 8, 2025▲ +23.2%on this news· ran to +114% by day 3
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations
New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., May 08, 2025 (GLOBE NEW
Read more →-NKGN
Mar 4, 2025▼ -62.9%on this news
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Trading commencing on the OTC Markets on March 5, 2025. Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants. NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing
Read more →-NKGN
Nov 26, 2024▲ +14.7%on this news
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a notice (the “Notice”) on November 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating th
Read more →-NKGN
Aug 22, 2024NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
SANTA ANA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a standard notice (the “Notice”) on August 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) sta
Read more →-NKGN
Apr 15, 2023NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.’s non-genetically modified, enhanced and expanded NK cells have the potential to be a possible treatme
Read more →About NKGen Biotech, Inc.
BIOPHARMAWATCH ELITE
Trade the next NKGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime